Friday, October 10, 2025

October 10, 2025 at 11:04PM FDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)

The FDA has received reports of immune effector cell-associated enterocolitis (IEC-EC) in patients who received treatment with CARVYKTI.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/e03NM41

No comments:

Post a Comment